Healthcare
Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies
Innovation enables customizable catheter length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement therapy modalitiesMINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,678,592, covering the company’s Dual Lumen Catheter, a
About this update from Nuwellis, Inc.
Innovation enables customizable catheter length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement therapy modalities MINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,678,592, covering the company's Dual Lumen Catheter, a novel peripheral dual-lumen catheter designed for use with extracorporeal therapies, including ultrafiltration, dialysis, and continuous renal replacement therapy (CRRT) modalities. The patent was issued on July 14, 2026. It further expands Nuwellis' intellectual property portfolio and supports the Company's broader strategy of advancing differentiated technologies across the heart-kidney continuum. Nuwellis continues to invest in innovations that enhance fluid management therapies for both adult and pediatric patients. The new patent helps Nuwellis address a longstanding clinical challenge associated with extracorporeal therapies. During treatment, negative pressure generated by blood pumps can cause catheter collapse reducing blood flow and impacting therapy performance. Nuwellis' patented design incorporates a reinforcing stainless-steel coil that helps maintain catheter patency under negative pressure while introducing an innovative design that allows clinicians to trim the catheter to an appropriate length for individual patients without compromising its structural integrity. The ability to customize catheter length while maintaining resistance to collapse may improve achievable blood flow, support longer extracorporeal filter life, and provide greater flexibility when treating patients of varying sizes. "Effective vascular access is fundamental to the performance of extracorporeal therapies," said Nuwellis' CEO Mike McCormick. "This patent represents another example of our commitment to developing practical innovations that address real-world clinical challenges. By combining resistance to catheter collapse with the ability to customize catheter length for individual patients, this technology can improve therapy performance and provides clinicians with greater flexibility across a broad range of patient populations." About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis' portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com .